Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
Company profile
Ticker
CRNX
Exchange
Website
CEO
Dr. R. Scott Struthers Ph.D.
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
KSIX Media Holdings, Inc., Mar Ked Mineral Exploration, Inc., NORTH AMERICAN ENERGY RESOURCES, INC., North American Energy Resources, Inc., Surge Holdings, Inc.
SEC CIK
CRNX stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
16 Oct 24
8-K
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
9 Oct 24
424B5
Prospectus supplement for primary offering
9 Oct 24
424B5
Prospectus supplement for primary offering
8 Oct 24
8-K
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
26 Sep 24
8-K
Departure of Directors or Certain Officers
17 Sep 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results
8 Aug 24
424B5
Prospectus supplement for primary offering
21 Jun 24
8-K
Other Events
21 Jun 24
Latest ownership filings
SC 13G/A
STATE STREET CORP
17 Oct 24
4
Dana Pizzuti
7 Oct 24
144
Notice of proposed sale of securities
3 Oct 24
4
Marc Wilson
30 Sep 24
144
Notice of proposed sale of securities
26 Sep 24
4
Stephen F. Betz
12 Sep 24
144
Notice of proposed sale of securities
10 Sep 24
4
Stephen F. Betz
28 Aug 24
144
Notice of proposed sale of securities
26 Aug 24
4
Stephen F. Betz
14 Aug 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 303.46 mm | 303.46 mm | 303.46 mm | 303.46 mm | 303.46 mm | 303.46 mm |
Cash burn (monthly) | 31.25 mm | (no burn) | 27.59 mm | 23.16 mm | 15.21 mm | 14.86 mm |
Cash used (since last report) | 117.36 mm | n/a | 103.62 mm | 86.98 mm | 57.10 mm | 55.80 mm |
Cash remaining | 186.10 mm | n/a | 199.84 mm | 216.49 mm | 246.36 mm | 247.66 mm |
Runway (months of cash) | 6.0 | n/a | 7.2 | 9.3 | 16.2 | 16.7 |
Institutional ownership, Q2 2024
96.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 236 |
Opened positions | 55 |
Closed positions | 18 |
Increased positions | 97 |
Reduced positions | 56 |
13F shares | Current |
---|---|
Total value | 3.31 tn |
Total shares | 86.93 mm |
Total puts | 196.80 k |
Total calls | 268.00 k |
Total put/call ratio | 0.7 |
Largest owners | Shares | Value |
---|---|---|
BLK BlackRock | 6.23 mm | $279.06 bn |
Driehaus Capital Management | 6.11 mm | $273.76 bn |
Wellington Management | 4.62 mm | $206.95 bn |
Vanguard | 4.51 mm | $202.20 bn |
T. Rowe Price | 4.41 mm | $197.37 mm |
EcoR1 Capital | 4.16 mm | $186.12 bn |
FMR | 4.10 mm | $183.50 bn |
STT State Street | 2.81 mm | $125.99 bn |
Point72 Asset Management | 2.78 mm | $124.55 bn |
Jennison Associates | 2.78 mm | $124.52 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
3 Oct 24 | Dana Pizzuti | Common Stock | Sell | Dispose S | No | Yes | 54.63 | 14,375 | 785.31 k | 28,507 |
3 Oct 24 | Dana Pizzuti | Common Stock | Option exercise | Acquire M | No | No | 16.89 | 14,375 | 242.79 k | 42,882 |
3 Oct 24 | Dana Pizzuti | Stock option Common Stock | Option exercise | Dispose M | No | No | 16.89 | 14,375 | 242.79 k | 139,042 |
26 Sep 24 | Marc Wilson | Common Stock | Sell | Dispose S | No | Yes | 51.11 | 25,000 | 1.28 mm | 111,092 |
26 Sep 24 | Marc Wilson | Common Stock | Option exercise | Acquire M | No | No | 15.29 | 25,000 | 382.25 k | 136,092 |
26 Sep 24 | Marc Wilson | Stock option Common Stock | Option exercise | Dispose M | No | No | 15.29 | 25,000 | 382.25 k | 89,000 |
10 Sep 24 | Stephen F. Betz | Common Stock | Sell | Dispose S | No | Yes | 51.5 | 1,035 | 53.30 k | 68,576 |
26 Aug 24 | Stephen F. Betz | Common Stock | Sell | Dispose S | No | Yes | 53.19 | 3,000 | 159.57 k | 69,611 |
12 Aug 24 | Stephen F. Betz | Common Stock | Sell | Dispose S | No | Yes | 47.68 | 3,000 | 143.04 k | 72,611 |
News
Reported Earlier, Crinetics Pharmaceuticals Prices $500M Upsized Public Offering Of 10M Common Shares At $50/Share
9 Oct 24
What Analysts Are Saying About Crinetics Pharmaceuticals Stock
27 Sep 24
JMP Securities Reiterates Market Outperform on Crinetics Pharmaceuticals, Maintains $80 Price Target
27 Sep 24
Crinetics Submits New Drug Application For Paltusotine For The Proposed Treatment And Long-Term Maintenance Therapy Of Acromegaly
26 Sep 24
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target
16 Sep 24
Press releases
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
16 Oct 24
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10 Oct 24
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
8 Oct 24
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
8 Oct 24
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
26 Sep 24